Australia markets closed

Lumos Pharma, Inc. (LUMO)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.71+0.29 (+3.91%)
At close: 04:00PM EDT
Show:
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2021
31/12/2020
31/12/2019
31/12/2018
Total revenue
341
230
168
936
12,474
Operating expenses
Research development
15,807
16,246
9,206
22,205
45,694
Selling general and administrative
14,995
15,331
17,265
23,865
29,218
Total operating expenses
30,802
31,577
26,471
46,070
74,912
Operating income or loss
-30,461
-31,347
-26,303
-45,134
-62,438
Interest expense
98
-
-
50
52
Total other income/expenses net
255
269
6,467
-19
-102
Income before tax
-30,155
-31,066
-19,636
-42,977
-60,563
Income tax expense
-
-636
-13,973
12
-6,968
Income from continuing operations
-29,519
-30,430
-5,663
-42,989
-53,595
Net income
-29,519
-30,430
-5,663
-42,989
-53,595
Net income available to common shareholders
-29,519
-30,430
-6,314
-42,989
-53,595
Basic EPS
-
-3.65
-0.93
-10.35
-12.96
Diluted EPS
-
-3.65
-0.93
-10.35
-12.96
Basic average shares
-
8,335
6,778
4,144
4,132
Diluted average shares
-
8,335
6,778
4,144
4,132
EBITDA
-
-31,144
-25,719
-41,833
-59,366